These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
443 related articles for article (PubMed ID: 36593888)
1. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study. Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T; JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888 [TBL] [Abstract][Full Text] [Related]
2. Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies. Reimer P; Vilgrain V; Arnold D; Balli T; Golfieri R; Loffroy R; Mosconi C; Ronot M; Sengel C; Schaefer N; Maleux G; Munneke G; Peynircioglu B; Sangro B; Kaufmann N; Urdaniz M; Pereira H; de Jong N; Helmberger T Cardiovasc Intervent Radiol; 2024 Mar; 47(3):310-324. PubMed ID: 38321223 [TBL] [Abstract][Full Text] [Related]
3. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT). Helmberger T; Golfieri R; Pech M; Pfammatter T; Arnold D; Cianni R; Maleux G; Munneke G; Pellerin O; Peynircioglu B; Sangro B; Schaefer N; de Jong N; Bilbao JI; ; Cardiovasc Intervent Radiol; 2021 Jan; 44(1):21-35. PubMed ID: 32959085 [TBL] [Abstract][Full Text] [Related]
4. Prognostic Factors for Effectiveness Outcomes After Transarterial Radioembolization in Metastatic Colorectal Cancer: Results From the Multicentre Observational Study CIRT. Schaefer N; Grözinger G; Pech M; Pfammatter T; Soydal C; Arnold D; Kolligs F; Maleux G; Munneke G; Peynircioglu B; Sangro B; Pereira H; Zeka B; de Jong N; Helmberger T; Clin Colorectal Cancer; 2022 Dec; 21(4):285-296. PubMed ID: 36270925 [TBL] [Abstract][Full Text] [Related]
5. ALBI grade for outcome prediction in patients affected by hepatocellular carcinoma treated with transarterial radioembolization. Gelardi F; Rodari M; Pini C; Zanca R; Artesani A; Tosi G; Chiti A; Sollini M Front Nucl Med; 2022; 2():934446. PubMed ID: 39354974 [TBL] [Abstract][Full Text] [Related]
6. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342 [TBL] [Abstract][Full Text] [Related]
7. Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study. Maleux G; Albrecht T; Arnold D; Bargellini I; Cianni R; Helmberger T; Kolligs F; Munneke G; Peynircioglu B; Sangro B; Schaefer N; Pereira H; Zeka B; de Jong N; Bilbao JI; Cardiovasc Intervent Radiol; 2023 Jul; 46(7):852-867. PubMed ID: 36914788 [TBL] [Abstract][Full Text] [Related]
8. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life. Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814 [TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study. Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511 [TBL] [Abstract][Full Text] [Related]
10. Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis. Hur MH; Cho Y; Kim DY; Lee JS; Kim GM; Kim HC; Sinn DH; Hyun D; Lee HA; Seo YS; Lee IJ; Park JW; Kim YJ Clin Mol Hepatol; 2023 Jul; 29(3):763-778. PubMed ID: 37254488 [TBL] [Abstract][Full Text] [Related]
11. Resin Versus Glass Microspheres for Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436 [TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization. Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison. Agirrezabal I; Bouattour M; Pinato DJ; D'Alessio A; Brennan VK; Carion PL; Shergill S; Amoury N; Vilgrain V Eur J Cancer; 2024 Jan; 196():113427. PubMed ID: 37988840 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S; J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371 [TBL] [Abstract][Full Text] [Related]
15. Objective Tumor Response of Hepatocellular Carcinoma Obtained by Transarterial Radioembolization with Iodine-131-Lipiodol Versus Transarterial Chemoembolization for Patients with and without Portal Venous Thrombosis: A Controlled Interventional Trial. Oliveira Ribeiro MC; Moda KA; Alvarez M; Koga KH; Moriguchi SM; Carvalho FC; Pinheiro RSN; Qi X; Romeiro FG Acad Radiol; 2024 May; 31(5):1839-1848. PubMed ID: 38016824 [TBL] [Abstract][Full Text] [Related]
16. Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086 [TBL] [Abstract][Full Text] [Related]
17. Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C). Goswami P; Adeniran OR; K Frantz S; Matsuoka L; Du L; Gandhi RT; Collins ZS; Matrana MR; Petroziello M; Brower JS; Sze DY; Kennedy AS; Golzarian J; Wang EA; Brown DB BMC Gastroenterol; 2022 Nov; 22(1):467. PubMed ID: 36396989 [TBL] [Abstract][Full Text] [Related]
18. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis. Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644 [TBL] [Abstract][Full Text] [Related]
19. Survival and Toxicities after Emmons EC; Bishay S; Du L; Krebs H; Gandhi RT; Collins ZS; O'Hara R; Akhter NM; Wang EA; Grilli C; Brower JS; Peck SR; Petroziello M; Abdel Aal AK; Golzarian J; Kennedy AS; Matsuoka L; Sze DY; Brown DB Radiology; 2022 Oct; 305(1):228-236. PubMed ID: 35762890 [TBL] [Abstract][Full Text] [Related]